Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

337P - Neutrophil-to-Lymphocyte ratio as a predictive factor for hyperprogressive disease in NSCLC patients treated with immune checkpoint inhibitor

Date

23 Nov 2019

Session

Poster display session

Topics

Immunotherapy

Tumour Site

Non-Small Cell Lung Cancer

Presenters

Ryo Takahashi

Citation

Annals of Oncology (2019) 30 (suppl_9): ix107-ix114. 10.1093/annonc/mdz438

Authors

R. Takahashi1, E. Shibata1, T. Higashiyama1, T. Kamei1, A. Tada1, H. Ishigaki1, Y. Nakajima1, Y. Negi1, M. Niki1, K. Mikami2, T. Minami1, T. Yokoi3, K. Kuribayashi1, T. Kijima2

Author affiliations

  • 1 Dept. Of Internal Medicine, Hyogo College of Medicine, 663-8501 - Nishinomiya/JP
  • 2 Internal Medicine Department, Hyogo College of Medicine, 663-8501 - Nishinomiya/JP
  • 3 Department Of Thoracic Oncology, Hyogo College of Medicine, 663-8501 - Nishinomiya/JP

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 337P

Background

Hyperprogressive disease (HPD) has been reported as one of unfavorable responses during treatment with immunecheck point inhibitors for advanced non-small cell lung cancer (NSCLC) patients. However its mechanism remains unclear and the phenomenon itself remains controversial.

Methods

Medical records from consecutive NSCLC patients treated by monotherapy with anti-PD-1/PD-L1 antibodies at Hyogo College of Medicine Hospital between Jun 2016 and May 2018 were analyzed retrospectively. HPD criteria was defined as 1) time to treatment failure < 1 month and 2) tumor growth kinetics rate > 2. To explore the predictive factor for HPD, we examined the association between clinical parameters and responses.

Results

Ninety-four patients were treated with nivolumab. The median patient age was 70 (range 4188) years and 72 patients (73%) were male. Patients number of ECOG PS 0/1/2/3/4 were 15(16%)/59(60%)/18(19%)/2 (3%)/0 respectively. Fifty-two patients (55%) were diagnosed with adenocarcinoma, 38 (40%) were squamous cell carcinoma, and 4 (5%) were other types. We examined Neutrophil-to-lymphocyte ratio (NLR) at base line and relative change in the course of treatment, and the NLR of 48 (56%) patients were ≥ 3.0 and the other 46 (44%) were < 3.0. Among 94 patients, the best all over response were complete response 3 (3.2%), partial response 27 (28.7%), stable disease 35 (37.2%), progressive disease 25 (26.6%); non-HPD 21 (22.3%), HPD 4 (4.3%), and not evaluated 3 (3.2%). All of the 4 HPD patients were male with ECOG PS 1/2/2/3, and treated in 2nd-line therapy for adenocarcinoma. NLR for HPD patients at baseline were 1.62, 4.84, 9.31, 14.75 (median=2.80, range 0.62-19.9) and ΔNLR (relative change of NLR in the course) were 1.51, 3.44, 3.29, 4.26 (median=1.10, range 0.27-4.26).

Conclusions

Our study suggests that HPD exists in a fraction of patients treated immune checkpoint inhibitor and could be associated with high neutrophil-to-lymphocyte ratio. We will update and publish the data containing patients treated with other anti-PD-1/PD-L1 antibodies.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

T. Minami: Honoraria (institution): Taiho. T. Yokoi: Honoraria (institution): Ono; Honoraria (institution): Chugai; Honoraria (institution): MSD; Honoraria (institution): Bristol-Myeres; Honoraria (institution): AstraZeneca; Honoraria (institution): Taiho. K. Kuribayashi: Honoraria (institution): Ono; Honoraria (institution): Bristol-Myers Squibb. T. Kijima: Honoraria (institution), Speaker Bureau / Expert testimony, Research grant / Funding (self): Ono; Honoraria (institution), Speaker Bureau / Expert testimony, Research grant / Funding (institution): Bristol-Myeres; Honoraria (institution), Speaker Bureau / Expert testimony, Research grant / Funding (institution): Chugai; Honoraria (institution), Speaker Bureau / Expert testimony, Research grant / Funding (institution): MSD; Honoraria (institution), Speaker Bureau / Expert testimony, Research grant / Funding (institution): Taiho. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.